Children sought for Sore Throat Study to help develop Strep A vaccine

August 2, 2022

Research at a Glance:

  • More than 1000 children are being sought for a study to learn more about sore throats and how best to prevent them
  • The study, run by the Australian Strep A Vaccine Initiative (ASAVI), is recruiting 1050 healthy children, aged 3-14 years, in Melbourne and Perth
  • The study will investigate how many children get sore throats, what is the most common cause of sore throat and how sore throats can change during different seasons of the year
  • The information collected will help inform how a vaccine could be used to prevent a wide range of illnesses caused by Strep A

More than 1000 children are being sought for a study to learn more about sore throats and how best to prevent them.

The STAMPS study, led by Australian Strep A Vaccine Initiative (ASAVI) partners the Murdoch Children’s Research Institute (MCRI) and the Telethon Kids Institute, is recruiting 1050 healthy children, aged 3-14 years, in Melbourne and Perth.

Murdoch Children’s project lead Professor Andrew Steer said the study would investigate how many children got sore throats, what was the most common cause of a sore throat and how sore throats could change during different seasons of the year. The information collected will help inform how a vaccine could be used to prevent a wide range of illnesses caused by Strep A.

Strep A infections affect about 750 million people with more than 500,000 globally dying from complications every year – more than influenza, typhoid or whooping cough.

“Strep A is often responsible for mild infections like a sore throat, also called ‘strep throat’, and impetigo, which causes skin sores,” Professor Steer said. But when left untreated it can become life-threatening if the bacteria invades the body’s bloodstream, muscles or lungs, which can cause severe illnesses such as septicaemia, rheumatic heart disease and kidney disease.”

Strep A infections disproportionately affect young children, the elderly, pregnant women and Indigenous Australians. Rates of rheumatic heart disease among Indigenous populations in northern Australia are some of the highest in the world. There is currently no vaccine available to prevent Strep A and infection can only be treated with antibiotics.

“This study is an important step towards helping inform how a vaccine could be used to prevent a wide range of illnesses caused by Strep A,” Professor Steer said.

ASAVI co-director, Telethon Kids Institute Director Professor Jonathan Carapetis, said a Strep A vaccine wasurgently needed.

“A safe and effective Strep A vaccine is an important and practical solution for disease control, which will do so much to not only close the gap in Indigenous health in Australia but ease the burden of diseases caused by Strep A globally, particularly in developing countries,” he said.

Professor Steer said the global burden of Strep A was an unmet public health challenge.

“A vaccine for Strep A will save hundreds of thousands of lives every year and prevent millions of infections that send children and adults to the hospital or doctor,” he said.

The study will monitor children’s health for 12 months via three visits with the study team. Parents will be asked to complete surveys about their child’s health and wellbeing and collect blood samples and throat swabs. The team will also collect information from participants if they experience signs or symptoms of a sore throat.

For more information, visit the Sore Throat Study webpage.

Back to News & Insights

We are funded by the Australian Federal Government’s Medical Research Future Fund (MRFF) and our philanthropic partners.

  • Open Philanthropy
  • LEDUCQ